GSK has named Luke Miels as CEO Designate. He will take on full responsibilities as Chief Executive Officer and join the Board on January 1, 2026, succeeding Dame Emma Walmsley. Miels, currently GSK’s Chief Commercial Officer, has played a key role in expanding the company’s specialty medicines portfolio, particularly in oncology and respiratory. With over two decades of experience at AstraZeneca, Roche, and Sanofi-Aventis, Miels brings significant global biopharma expertise to the role. GSK, a biopharma company focused on uniting science, technology, and talent to get ahead of disease, is entering a pivotal phase aimed at exceeding its 2031 sales outlook of over $52 billion.
GSK Chair Sir Jonathan Symonds stated, “Luke has outstanding global biopharma development and commercial experience, together with a deep understanding of the company, its prospects, and its people. He is extremely well placed to lead, deliver and surpass the ambitions we have set for GSK, and to generate new growth and value for patients and shareholders.” Reflecting on his appointment, Miels said, “I am deeply honored to be appointed as the next CEO of GSK.” He added, “As the next CEO, I am privileged to take on this responsibility, with humility and ambition.”